Limb-Girdle Muscular Dystrophy (LGMD) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Limb-Girdle Muscular Dystrophy (LGMD) Emerging Therapy and TPP Insights

Thelansis's "Limb-Girdle Muscular Dystrophy (LGMD) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Limb-Girdle Muscular Dystrophy (LGMD) Overview

Limb-Girdle Muscular Dystrophy is a heterogeneous group of inherited myopathies caused by mutations affecting sarcolemmal, sarcomeric, or nuclear proteins, driving progressive proximal muscle degeneration. Patients present with shoulder and pelvic girdle weakness, waddling gait, and variable cardiac or respiratory involvement; laminopathy and sarcoglycanopathy subtypes carry particular arrhythmia risk requiring early pacemaker or ICD consideration. Diagnosis combines elevated CK, muscle biopsy immunohistochemistry, and genetic panel testing. While no universal cure exists, the paradigm is shifting toward genotype-targeted therapies, including AAV-based gene therapy and glycosylation-pathway modulators under active evaluation. Physiotherapy, orthotic support, and cardiorespiratory surveillance remain foundational. Multidisciplinary care preserves function and quality of life.

Key Highlights

• In France, prevalent LGMD cases are projected to increase from approximately 1,402 in 2025 to 1,499 by 2035.
• LGMD remains a rare genetic neuromuscular disorder associated with progressive muscle weakness and disability.
• Improved genetic testing is facilitating earlier diagnosis and subtype identification.
• Significant unmet need persists due to the absence of broadly effective disease-modifying therapies.
• Emerging gene therapy and genetic medicine approaches are reshaping the treatment landscape.

Market Overview

• The France LGMD market is projected to grow from approximately $170 MN to $510 MN by 2035.
• Market growth is supported by:
• Advancements in gene therapy development
• Increasing adoption of precision diagnostics and supportive care
• Market expansion is expected to be driven by high-value rare disease therapies.
• Future growth will depend on successful commercialization of gene-based and disease-modifying treatments.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Sarepta Therapeutics, Inc.
• ML Bio Solutions, Inc.
• AskBio Inc.
• Atamyo Therapeutics